NASDAQ OMX

DSM Sinochem Pharmaceuticals successfully launches Rosuvastatin finished dosage formulation in Western Europe

Dela

Rijswijk, Netherlands, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Upon patent expiry at the end of December 2017, DSM Sinochem Pharmaceutical (DSP) has successfully launched its fully backward integrated, generic Rosuvastatin drug product in multiple Western European countries. The successful launch will be extended to additional countries prior to the end of January, among which is the Netherlands.

After being one of the first companies globally to receive a CEP in early 2016 for Rosuvastatin API, DSP again proves to be a frontrunner by being one of the first to launch Rosuvastatin drug products in Western Europe using its in-house produced API.

Statins are currently the most prescribed drug class globally for high cholesterol and cardiovascular diseases and are among the top selling drugs worldwide. Rosuvastatin is used for reducing high cholesterol and preventing cardiovascular disease, which is the number one cause of death worldwide.

Quality, Reliability and Sustainability

In line with its brand promise of Quality, Reliability and Sustainability, DSP's Rosuvastatin offers customers superior performance in all three areas. For its finished dosage formulations, DSP uses its own in-house manufactured API. This proprietary, backward integrated, process, which is protected by 10 patent families, involves a highly efficient enzymatic coupling step, and offers customers independence from third party intermediate suppliers. Additional advantages to its API include unrivalled product quality with an assay of >99% and large batch sizes of 200 kg. This further results in significantly reduced Quality Assurance and testing costs, the absence of hazardous residual chemicals and a 35% reduced carbon footprint related to production.

Expanding portfolio

With the successful launch of the Rosuvastatin finished dosage formulation, on top of the earlier successful launch of DSP's beta lactam drug products, and the upcoming launch of Atorvastatin in Europe by summer 2018, the company is quickly expanding its drug product portfolio. What sets DSP apart from competitors is its backward integration and full control of its supply chain.

CEO, Karl Rotthier: "I am proud that our company, together with our partners, is among the first worldwide to launch a generic Rosuvastatin finished dosage formulation in Western Europe upon patent expiration; after being one of the first to offer the Rosuvastatin API under CEP. This shows our dedication to excellence and our aspiration to continue to be an industry leader".

BU Director Drug Products, Lucas Wiarda: "As with every one of our products, Rosuvastatin delivers superior performance on quality, reliability and sustainability compared to the industry average. This is largely due to DSP's full control of its manufacturing process from start to finish. Building on our strong position in beta lactams, Rosuvastatin is an excellent addition to our drug products portfolio which we proudly offer to our customers."

Currently DSP holds an eCTD dossier for Rosuvastatin finished dosage formulations (5,10,20 & 40mg FCT) containing Zone II & IV stability data and a 36 month shelf life.

About DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Erin van Wijngaarden, Manager PR & Corporate Communications. E-Mail: communications@dsm-sinochem.com

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7ac00118-d5bc-405d-a32d-b02d5c584c11

Erin van Wijngaarden
DSM Sinochem Pharmaceuticals
communications@dsm-sinochem.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM Sinochem Pharmaceuticals via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa19.1.2018 14:00Pressmeddelande

Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The oral presentation titled, "An open-label extension study of MABp1 targeting interleukin-1alpha for hidradenitis suppurativa (HS)" will be given by Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens Greece, on 8 February 2018 between 1:50 and 2:50pm local time. The findings being presented come from patients that had received placebo in

The Search for #AconfidentYou Role Models Kicks Off at the Xehar Fashion Fairies Conference19.1.2018 12:00Pressmeddelande

Expanding their Fashion Fairies Program, Xehar Teaches and Inspires Women Through Confidence EL SEGUNDO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Today, the Xehar team announces the Xehar Fashion Fairies Conference, which takes place over three days in Los Angeles, January 19th-21st. The conference gathers aspiring fashionistas to celebrate self love, natural beauty, and learn what it takes inspire women to be more confident. With powerful keynotes, exciting breakout sessions, a fashion show and international networking opportunities, the conference is a unique blend that is new to the fashion industry. "We are searching for our 2018 Fashion Fairies who are serious about a career in fashion and want to inspire women worldwide," says Hadari Oshri, founder and CEO of Xehar. "Attendees will learn how to become one of our exclusive #AconfidentYou Fashion Fairies." Propelled by the successful launch of its existing influencer outreach, Xehar has now expanded their Fashion Fairies program t

Olympus Labs Partners with Leading Korean Fintech Company Metaps Plus19.1.2018 00:03Pressmeddelande

Gibraltar, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Olympus Labs is quickly becoming an emerging global leader in the cryptocurrency-based financial product space, and on the heels of a successful token sale, Olympus is partnering with Seoul-based corporation Metaps Plus, a leading Korean fintech company and mobile marketing platform developer. This news comes shortly after the company announced OKEx, as its official exchange for the company's token MOT. "This is an amazing partnership for us, as it will allow us to hit the Korean market in a big way. We will be able to tap directly into the tens of millions of users on the Metaps Plus platform, allowing users to access financial products created by Olympus," said Kai Chen, CEO of Olympus Labs. "This is a key milestone as it demonstrates that Olympus products can be integrated in third party platforms such as mobile apps, wallets, exchanges, and even physical atms and pos systems, allowing users throughout the world access to Olympus products

Forward Industries Acquires Intelligent Product Solutions18.1.2018 23:54Pressmeddelande

WEST PALM BEACH, Fla. and HAUPPAUGE, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Forward Industries (NASDAQ:FORD) today announced the acquisition of Intelligent Product Solutions (IPS), an industry leading product design and development company based in Long Island, New York for a material consideration comprising of cash, equity, and contingent earn outs. IPS clients include leading brands in consumer electronics, medical devices, enterprise and security solution providers and Internet of Things connected solutions, including Google, Physio Control, PepsiCo, Motorola, ABInBev, Zebra and Charity Water. Commenting on the transaction, Terry Wise, CEO of Forward Industries remarked, "I am delighted and excited with the acquisition of IPS. The company is an excellent strategic fit for Forward Industries. Its expertise and strong track record in designing connected/IOT products and developing products such as the AdhereTech 'smart' pill bottle will significantly strengthen and contribute to For

VITEC to Highlight EZ TV IPTV and Digital Signage Platform in First ISE Appearance18.1.2018 21:06Pressmeddelande

PARIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In its first-ever attendance at Integrated Systems Europe (ISE), VITEC, a worldwide leader in advanced video encoding and streaming solutions, will showcase EZ TV - a market-leading, broadcast-grade IPTV and digital signage platform with key installations in Europe and the U.S. Targeted to enterprises, sports stadiums and arenas, and government agencies, EZ TV combines low-latency, broadcast-quality IPTV distribution with powerful digital signage capabilities to give audiences a more engaging and interactive experience. "As Europe's largest show for AV systems integrators, ISE is the perfect forum for us to present our EZ TV IPTV platform," said Bruno Teissier, sales and marketing director, VITEC. "We're looking forward to showing ISE attendees how they can help their customers distribute broadcast-quality IPTV content and access powerful digital signage capabilities in an all-in-one, integrated solution." Designed to integrate seamlessly with a

Brookfield Asset Management Notice of 2017 Year End Results Conference Call and Webcast18.1.2018 16:12Pressmeddelande

Date: Thursday, February 15, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, News, Jan. 18, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Year End Results Conference Call & Webcast on Thursday, February 15, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on February 15th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-521-4909 toll free in North America, or for overseas calls please dial 1-647-427-2311 at approximately 10:50 a.m. The Conference Call will also be Webcast live at https://event.on24.com/wcc/r/1585364/9F53C4FB4A83FF2D32296C84535D6A34. For those unable to participate

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum